Inspiring Patients to Take a Shortcut to Better Health

Unique Cost-effective Solution for Diabetes Patients
Insulair®, build on pMDI technology, is uniquely designed for use with liquid drug formulations including the treatment of diabetes. It is widely anticipated that the shift to a more cost-efficient drug delivery mechanism will represent a reduction in cost for the treatment of diabetes patients with inhaled insulin and could enable a wider population segment to avail of a more effective treatment. Reduction in cost is due to the use of a reservoir technology which reduces the daily cost of administering the treatment.

Benefits of Reduced Costs
. More acceptable inhaler solution for Healthcare authorities
. Wider population can be treated (more inhalers can be produced)
. More attractive positioning for reimbursement claims

Breath-Actuated Mechanism
. Easy to use breath-actuated mechanism provides easy co-ordination for the user.

Reliable Integrated Dose-counter
. The integrated dose-counter tracks 200 individual doses and counts in single increments once a dose is released
. The dose-counter has a special design that only registers fired doses, allowing for reliable and accurate readings
. The dose-counter enables patients to remain compliant to their medication regimes

Innovative Valve Technology
. The innovative valve technology allows for flexible dosing requirements.

Particle Flow Rate Reduction
. A unique technology reduces the particle flow rate and thereby ensures improved drug delivery to the patient’s lungs.

Easy-to-use, Compact Design
. Convenient, easy-to-use compact design is easy to store and transport.

Development Programmes and Licensing
Please contact Bang & Olufsen Medicom for more information.

More information on Insular®
For requirements and further information about Insulair® please contact Bang & Olufsen Medicom